13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
16 檔
52.6%
In Q4 2025, BML Capital Management, LLC's U.S. equity holdings reached a combined market value of $175.7M, distributed across 16 disclosed stock positions.
In Q4 2025, BML Capital Management, LLC adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 9 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 37.08% | +1.74% | — | |
| 2 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 23.11% | -5.98% | +0.21% | |
| 3 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 7.80% | -4.54% | — | |
| 4 | TIL | Instil Bio Inc | Stock-Other | 6.14% | -0.59% | — | |
| 5 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 5.72% | -0.18% | — | |
| 6 | KMX | Carmax Inc | Stock-Consumer Disc | 5.18% | +1.05% | — | |
| 7 | 2KZ0 | Kezar Life Sciences Inc | Stock-Other | 3.92% | -3.43% | EXIT | |
| 8 | TGT | Target CORP | Stock-Consumer Disc | 3.17% | -0.13% | +275.00% | |
| 9 | CVNA | Carvana Co | Stock-Consumer Disc | 1.74% | — | — | |
| 10 | OM | Outset Medical Inc | Stock-Other | 1.74% | +1.51% | — | |
| 11 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.63% | -0.25% | — | |
| 12 | IMA | Imagenebio Inc | Stock-Other | 1.06% | +0.03% | -3.00% | |
| 13 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 1.00% | +0.09% | -67.74% | |
| 14 | WMT | Walmart Inc | Stock-Consumer Staples | 0.43% | -0.19% | +26.42% | |
| 15 | TSLA | Tesla Inc | Stock-Consumer Disc | 0.18% | +0.15% | NEW | |
| 16 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.12% | — | -33.22% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics Inc | +12.3% | — | Unchanged |
| 2 | AVIR | Atea Pharmaceuticals Inc | +3.3% | +0.21% | Add |
| 3 | TGT | Target CORP | +2.4% | +275.00% | Add |
| 4 | 2KZ0 | Kezar Life Sciences Inc | +1.4% | — | Unchanged |
| 5 | ORMP | Oramed Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 6 | WMT | Walmart Inc | -0.1% | +26.42% | Add |
| 7 | LSTA | Lisata Therapeutics Inc | -0.1% | -33.22% | Trim |
| 8 | IMA | Imagenebio Inc | -0.3% | -3.00% | Trim |
| 9 | ✓ | Connect Biopharma Hldgs LTD | -0.8% | -67.74% | Trim |
| 10 | PMVP | Pmv Pharmaceuticals Inc | -1.1% | — | Unchanged |
| 11 | TIL | Instil Bio Inc | -4.4% | — | Unchanged |
| 12 | AVU0 | Adverum Biotechnologies Inc | — | EXIT | Sold out |
| 13 | KMX | Carmax Inc | — | NEW | New buy |
| 14 | ALMS | Alumis Inc | — | EXIT | Sold out |
| 15 | ✓ | Lava Therapeutics NV | — | EXIT | Sold out |
| 16 | CVNA | Carvana Co | — | NEW | New buy |
| 17 | OM | Outset Medical Inc | — | NEW | New buy |
| 18 | PLRX | Pliant Therapeutics Inc | — | NEW | New buy |
| 19 | LONA | Leonabio Inc | — | EXIT | Sold out |
| 20 | ASTC | Astrotech CORP | — | EXIT | Sold out |
| 21 | VTGN | Vistagen Therapeutics Inc | — | EXIT | Sold out |
| 22 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 23 | TSLA | Tesla Inc | — | NEW | New buy |
| 24 | ✓ | Mural Oncology Pub LTD Co | — | EXIT | Sold out |
| 25 | ✓ | Third Harmonic Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 16 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACRS, AVIR, ORMP) accounted for 52.6% of total reported equity market value during Q4 2025.
Top New Position Initiated
KMX
市值: $6.0M
Top Position Liquidated / Trimmed
AVU0
前期市值: $13.9M
During Q4 2025, BML Capital Management, LLC's top holdings by market value included ACRS (37.1%)、AVIR (23.1%)、ORMP (7.8%). The largest single position, ACRS, represented 37.1% of total portfolio value.
In Q4 2025, BML Capital Management, LLC made 20 total portfolio adjustments, initiating 5 new buys, adding to 3 positions, trimming 3 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.